With a commitment to innovation, AFT Pharmaceuticals develops, licenses and sells a wide range of products to help improve the health and wellbeing of people.
About AFT Pharmaceuticals.
Read More
Pharmaceuticals
with a difference
Browse latest news
We develop, license, and sell pharmaceutical products in Australasia and around the world. Check out our latest news.
Read More
Our range of innovative products
Learn more about our range of products.
Read More
Kiwis Thinking About Health
Kiwis Thinking About Health is an initiative from AFT Pharmaceuticals that’s designed to help New Zealanders live a healthier life.
Read More
Aussies Thinking About Health
Aussies Thinking About Health is an initiative from AFT Pharmaceuticals that’s designed to help Australians live a healthier life.
Read More
Our range of innovative products
Learn more about our range of products
Browse our products
Please select your region below to view products
Our Initiatives
Kiwis Thinking About Health
Kiwis Thinking About Health is an initiative from AFT Pharmaceuticals that’s designed to help New Zealanders live a healthier life.
Our Initiatives
Aussies Thinking About Health
Aussies Thinking About Health is an initiative from AFT Pharmaceuticals that’s designed to help Australians live a healthier life.
AFT adds COMBOGESIC® (acetaminophen and ibuprofen) Tablets to Hikma Agreement in US.
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces an Agreement with Hikma Pharmaceuticals USA (“Hikma”) to distribute its patented1 COMBOGESIC® Tablets, a fixed dose combination (FDC) (acetaminophen and ibuprofen), non-opioid analgesia in a single tablet for adult pain management to select markets in the United States, the largest pharma market in the world.2 The Agreement […]
Read More
AFT Licenses Maxigesic® IV in Brazil
We are delighted to announce our partnership with Brazil’s Halex Istar, and to be exclusively responsible for distributing its Maxigesic IV in Brazil.
Read More
AFT, Massey Ventures, Gilles McIndoe to develop scar treatment
AFT collaborate with Massey Ventures and Gilles McIndoe to begin the development of a topical treatment for keloid and hypertrophic scarring.
Read More